Tozasertib (VX-680, MK-0457)

Catalog No.S1048

Tozasertib (VX-680, MK-0457) Chemical Structure

Molecular Weight(MW): 464.59

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 61 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.
Targets
Aurora A [1]
(Cell-free assay)
Aurora C [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
FLT3 [4]
(Cell-free assay)
Bcr-Abl [4]
(Cell-free assay)
0.6 nM(Ki app) 4.6 nM(Ki app) 18 nM(Ki app) 30 nM(Ki) 30 nM(Ki)
In vitro

Although its multi-kinase profile, VX-680 induces similar cytotoxicity with IC50 of approximately 300 nM and exhibits an AUR B-like inhibitory phenotype of G2/M arrest, endoreduplication and apoptosis in BaF3 cells transfected with ABL or FLT-3 (mutant and wild type) kinases. VX-680 prevents the CAL-62 proliferation in a time-dependent manner. VX-680 treatment for 14 days significantly decreases the number and size of colonies by approximately 70% in the 8305C and 90% in the CAL-62, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibits proliferation with the IC50 between 25 and 150  nM. The VX-680 significantly impairs the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity indicates that VX-680 induces apoptosis in the different cell lines. CAL-62 cells exposed for 12  hours to VX-680 showed an accumulation of cells with ≥4N DNA content. Time-lapse analysis demonstrates that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation is abrogated following VX-680 treatment. [2] VX-680 has significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BE-13 MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvmO3VKSzVyPUCuNFA{OzhizszN M1HFeHNCVkeURWK=
RS4-11 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW3TWM2OD1yLkCwOFA1KM7:TR?= M1HhWXNCVkeURWK=
MFH-ino NXzqXG9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMEC5PUDPxE1? M4HXTnNCVkeURWK=
NTERA-S-cl-D1 NIH6S4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[0elBNUUN3ME2wMlAyPDN2IN88US=> NEX0VpBUSU6JUlXS
697 NXvWS4VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PyT2lEPTB;MD6wNlQ4OSEQvF2= NYLDbGdWW0GQR2LFVi=>
NALM-6 NGT2SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H6cWlEPTB;MD6wNlU2OiEQvF2= M2PiVHNCVkeURWK=
ES8 M3r5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HnbGlEPTB;MD6wOFYyOyEQvF2= MoPpV2FPT1KHUh?=
HUTU-80 NVy5fo9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TCVGlEPTB;MD6wOVI6QSEQvF2= MUPTRW5IWkWU
MV-4-11 NILYN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G1O2lEPTB;MD6wO|c5OiEQvF2= M{\VXHNCVkeURWK=
MONO-MAC-6 M3jQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETOcnRKSzVyPUCuNFc5PzlizszN MVnTRW5IWkWU
LC-2-ad NEPjOGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XZSGlEPTB;MD6wPFc5QSEQvF2= NF;a[2VUSU6JUlXS
BL-41 M1fqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XpW2lEPTB;MD6xNFQ1PSEQvF2= M2PGenNCVkeURWK=
A4-Fuk NWK1TJpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDtOpJKSzVyPUCuNVE2PjNizszN MmTFV2FPT1KHUh?=
SW954 MmH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMUKyNlkh|ryP NX\tXZhuW0GQR2LFVi=>
BV-173 NHXYd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHwTWM2OD1yLkGyOlQyKM7:TR?= M2Lo[nNCVkeURWK=
TE-11 M{jETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[0SmZIUUN3ME2wMlE1QTh{IN88US=> NXzTNFN5W0GQR2LFVi=>
SK-UT-1 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofpTWM2OD1yLkG1PVY2KM7:TR?= MlHHV2FPT1KHUh?=
SIG-M5 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljpTWM2OD1yLkG2O|A4KM7:TR?= MlfHV2FPT1KHUh?=
OCUB-M NV7nN4pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHHTWM2OD1yLkG2PVg{KM7:TR?= NUX0fpJSW0GQR2LFVi=>
K052 MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm4TWM2OD1yLkG5OFgh|ryP Mki5V2FPT1KHUh?=
VA-ES-BJ MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnTbYVKSzVyPUCuNlAxQDZizszN MVPTRW5IWkWU
SW982 Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7hdnFpUUN3ME2wMlIyOzhizszN MlHyV2FPT1KHUh?=
LB647-SCLC NVXOUlVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7KeGE{UUN3ME2wMlIyPTJ|IN88US=> M4LyOHNCVkeURWK=
PSN1 NVTPclFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XUOWlEPTB;MD6yNlAzPiEQvF2= M1;mS3NCVkeURWK=
BB30-HNC M3G4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTrTWM2OD1yLkKyOVkyKM7:TR?= NI[xSWZUSU6JUlXS
ST486 M1znd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXnR|ZtUUN3ME2wMlI{ODh5IN88US=> NYnr[lQ1W0GQR2LFVi=>
MOLT-4 Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL0TWM2OD1yLkKzN|M4KM7:TR?= M2rscXNCVkeURWK=
EW-16 MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMkO3Olgh|ryP NFqwUohUSU6JUlXS
KS-1 MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYe3PYk1UUN3ME2wMlI{Pzh3IN88US=> NEfzUWFUSU6JUlXS
SR NF;TRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDSTWM2OD1yLkK0OVY1KM7:TR?= M3jmTXNCVkeURWK=
KM12 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMk[zOkDPxE1? MVvTRW5IWkWU
EM-2 MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPuPXQxUUN3ME2wMlI3PjRzIN88US=> NUjNTXR{W0GQR2LFVi=>
MEG-01 NYjSToRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkftTWM2OD1yLkK3PFQ6KM7:TR?= MWHTRW5IWkWU
NB13 M1PS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfhd5Q5UUN3ME2wMlI4QTh2IN88US=> MXzTRW5IWkWU
RKO NXfDfpFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwM{C4NVMh|ryP MWPTRW5IWkWU
CESS NF7XZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwM{GzNlgh|ryP NGGyPJVUSU6JUlXS
EoL-1-cell M{jlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXRTWM2OD1yLkOzOFU6KM7:TR?= M3\y[3NCVkeURWK=
DOHH-2 MlPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml22TWM2OD1yLkOzO|gyKM7:TR?= NFfySm1USU6JUlXS
A388 NVzrZ2VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nEVGlEPTB;MD6zOFA5PiEQvF2= NHrCbmRUSU6JUlXS
LAMA-84 NUm2O5ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3viWWlEPTB;MD6zOVE4QCEQvF2= NXHS[GxwW0GQR2LFVi=>
IMR-5 NVvrUpRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\OWGQzUUN3ME2wMlM2PTRizszN NHHJUGRUSU6JUlXS
KARPAS-422 MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3lSJg2UUN3ME2wMlM4Ojd{IN88US=> NFOwRnFUSU6JUlXS
MRK-nu-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwM{ixN{DPxE1? NFPwTXpUSU6JUlXS
BL-70 NFrlTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwM{i5O|Qh|ryP NWDBZo9YW0GQR2LFVi=>
LXF-289 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;VVnRTUUN3ME2wMlQxPDB4IN88US=> MoPxV2FPT1KHUh?=
RL95-2 NEjYeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTzSpRYUUN3ME2wMlQxPTZ5IN88US=> MYTTRW5IWkWU
QIMR-WIL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37jPWlEPTB;MD60NlY4PiEQvF2= MnXBV2FPT1KHUh?=
K-562 M4[xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\QWmlEPTB;MD60N|Q4OiEQvF2= NV7wbmYxW0GQR2LFVi=>
NCI-H510A NGXBeG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjVc3J5UUN3ME2wMlQ{QDJ|IN88US=> NUWydWlSW0GQR2LFVi=>
NCI-H524 NXv5S5ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LvTWlEPTB;MD61NVE1PyEQvF2= M4SwbHNCVkeURWK=
KE-37 M{\6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z3[GlEPTB;MD61NlExOiEQvF2= MnLvV2FPT1KHUh?=
KP-N-YS MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjITWM2OD1yLkW0N|kzKM7:TR?= M3HNWHNCVkeURWK=
LS-411N NEnVRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nTUGlEPTB;MD61O|c2OiEQvF2= NX;OOW5CW0GQR2LFVi=>
CTV-1 M1HFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO5TWM2OD1yLkW4O|c{KM7:TR?= Mn;kV2FPT1KHUh?=
NCI-SNU-16 NFv0UIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfrTWM2OD1yLk[zOVcyKM7:TR?= NIXxc4ZUSU6JUlXS
HT-144 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPQTWM2OD1yLk[zO|k5KM7:TR?= MWHTRW5IWkWU
NCI-H187 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPZTWM2OD1yLk[0NVMh|ryP NFXJNlRUSU6JUlXS
OCI-AML2 MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqxTWM2OD1yLk[0OFA{KM7:TR?= NHfqWZZUSU6JUlXS
CCRF-CEM M{nNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PETGlEPTB;MD62OVM1PiEQvF2= MUHTRW5IWkWU
ONS-76 MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\4NmZKSzVyPUCuOlY1PThizszN M2PGTHNCVkeURWK=
IST-SL2 NUjHT2doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwN{G5PFIh|ryP M4Sxd3NCVkeURWK=
NB6 NH2zR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:2VXRRUUN3ME2wMlc4OjV2IN88US=> MUfTRW5IWkWU
SK-PN-DW MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXW[XNKSzVyPUCuO|kyPCEQvF2= MVfTRW5IWkWU
HCC1599 NHPGNFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLKTWM2OD1yLkiwPFc1KM7:TR?= NYLjR5dKW0GQR2LFVi=>
MC116 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3zZ5hKSzVyPUCuPFUxOTFizszN M4rKN3NCVkeURWK=
TE-15 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwOEWwPVgh|ryP NIf4ZlFUSU6JUlXS
HOP-62 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[2TWM2OD1yLki2N|I6KM7:TR?= NEj3Z2lUSU6JUlXS
TGBC24TKB M{WzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwOE[zPFUh|ryP MWLTRW5IWkWU
HCE-4 NEjYfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu1RXhKSzVyPUCuPFgxPjNizszN MnXGV2FPT1KHUh?=
ALL-PO NIfmfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjmS|N7UUN3ME2wMlg5OTd3IN88US=> MXHTRW5IWkWU
KGN Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7NTWM2OD1yLki5PVk2KM7:TR?= Mnq0V2FPT1KHUh?=
ML-2 MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL6VllKSzVyPUCuPVAzPTlizszN Mmm1V2FPT1KHUh?=
ES4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmxTWM2OD1yLkmxNVI5KM7:TR?= NYfZOlVSW0GQR2LFVi=>
SF126 NUfhZ5pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwOUS4NVkh|ryP MoH4V2FPT1KHUh?=
SK-N-DZ NFzsSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrw[49KSzVyPUCuPVYyQDlizszN M{XmV3NCVkeURWK=
HCC1187 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrGTWM2OD1zLkCwOVA2KM7:TR?= MoPlV2FPT1KHUh?=
DU-4475 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PRbWlEPTB;MT6wNVc2PiEQvF2= MVPTRW5IWkWU
NKM-1 MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LkWmlEPTB;MT6wNlc4PSEQvF2= MWjTRW5IWkWU
HL-60 Mlq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrlWmRvUUN3ME2xMlA3PTd2IN88US=> MmCyV2FPT1KHUh?=
SBC-1 NXHibIZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3Kd3lKSzVyPUGuNVI2PDJizszN NVr5ZYVpW0GQR2LFVi=>
TE-10 NVfpNmdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTFwMUK5OFYh|ryP NWrEc2RkW0GQR2LFVi=>
ETK-1 MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFwMUO2NVMh|ryP M1vGdnNCVkeURWK=
HAL-01 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTyOllnUUN3ME2xMlE3PzB7IN88US=> MYrTRW5IWkWU
BB65-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXxO3piUUN3ME2xMlE5ODB3IN88US=> NYTJOmw1W0GQR2LFVi=>
EW-1 NYXIXZNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DEZ2lEPTB;MT6xPFU3OiEQvF2= NYrZdWlTW0GQR2LFVi=>
SK-NEP-1 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTr[FZKSzVyPUGuNlEyOTFizszN MnzRV2FPT1KHUh?=
SK-LMS-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnvVIFUUUN3ME2xMlIzOjF{IN88US=> MXHTRW5IWkWU
DEL NYTCWlQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwMkW2OFMh|ryP NYn1UWtTW0GQR2LFVi=>
GT3TKB NXzJfG0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1njVmlEPTB;MT6yPFA2PyEQvF2= NHzKW|NUSU6JUlXS
MOLT-16 NWHkN3I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYThUYhXUUN3ME2xMlM2PDB3IN88US=> NIi5N3FUSU6JUlXS
CMK M4rUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7kfo5KSzVyPUGuOFIyOTdizszN NXjZUlc5W0GQR2LFVi=>
NB5 NWX1ZWNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\sXnQ2UUN3ME2xMlY1OjJ7IN88US=> MXTTRW5IWkWU
NCI-H1963 M17zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;GTplRUUN3ME2xMlcxPTh|IN88US=> NED4SmtUSU6JUlXS
KURAMOCHI NHnPTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPIU4lKSzVyPUGuO|g6OTFizszN MoHBV2FPT1KHUh?=
TE-8 NEn0WIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoCwTWM2OD1zLkiwN|Y5KM7:TR?= Moj2V2FPT1KHUh?=
NCI-H1304 M{L6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f1XWlEPTB;MT64N|A4OyEQvF2= M4jhenNCVkeURWK=
A101D NEDxXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q3SWlEPTB;MT64O|M6PSEQvF2= NYO3To1FW0GQR2LFVi=>
SCLC-21H NWPsNodRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLJTWM2OD1zLkm3NFU4KM7:TR?= NFS3N2JUSU6JUlXS
GB-1 NIjRRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJwMEG2OFch|ryP NHzhdYFUSU6JUlXS
KARPAS-45 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJwMEK2OVQh|ryP NG\ObmJUSU6JUlXS
ATN-1 NFfZNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu1V2V2UUN3ME2yMlAzQDV6IN88US=> MUfTRW5IWkWU
NCI-H720 M160UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjVSoVkUUN3ME2yMlA3OjR2IN88US=> NYTXd|lzW0GQR2LFVi=>
RPMI-6666 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfVTWM2OD1{LkG2NlA4KM7:TR?= MYnTRW5IWkWU
NB17 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfXTWM2OD1{LkK5Nlch|ryP MVLTRW5IWkWU
IST-SL1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jzbGlEPTB;Mj6yPVc3PSEQvF2= NEHaenhUSU6JUlXS
SH-4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33o[GlEPTB;Mj6zNlQ3QSEQvF2= MUTTRW5IWkWU
K5 M3;0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TXfmlEPTB;Mj60NFMyQSEQvF2= MUTTRW5IWkWU
OVCAR-4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HBXGlEPTB;Mj60OlE{KM7:TR?= MkDuV2FPT1KHUh?=
ACN Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJwNUCyNVMh|ryP MWfTRW5IWkWU
TGW MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;NR2lEPTB;Mj62OVg{OiEQvF2= NXHIUmNpW0GQR2LFVi=>
NCI-H2107 MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInkVlFKSzVyPUKuPFM4OTFizszN NE\GSo1USU6JUlXS
NCI-H82 M4rqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XsU2lEPTB;Mj64N|g{QCEQvF2= MYHTRW5IWkWU
SK-N-FI NEL0W|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz4TVFKSzVyPUKuPFY5PjhizszN MYjTRW5IWkWU
LB1047-RCC M2i1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJwOEixNlYh|ryP NVrs[5FGW0GQR2LFVi=>
LU-134-A MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Huc2lEPTB;Mj64PVI3KM7:TR?= M2\5OnNCVkeURWK=
NCI-H209 M2jhU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjmNm1uUUN3ME2yMlkyOjV|IN88US=> MXrTRW5IWkWU
NOMO-1 NV62WHJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nWXWlEPTB;Mz6wNlI4PCEQvF2= NIDUXWdUSU6JUlXS
RH-1 M1LBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ToOmlEPTB;Mz6xO|I6OSEQvF2= MX\TRW5IWkWU
LOUCY NWO3NG1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;0R3FYUUN3ME2zMlE5Pjl|IN88US=> M2D4VnNCVkeURWK=
TE-9 NWPWeFJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7nTWM2OD1|LkK2O|M3KM7:TR?= NXWzVmN3W0GQR2LFVi=>
PF-382 Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki0TWM2OD1|LkO1O|c5KM7:TR?= M4rMWnNCVkeURWK=
RPMI-8402 MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3PTWM2OD1|LkW4OlA{KM7:TR?= MWHTRW5IWkWU
HEL MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTDXZc5UUN3ME2zMlY{OiEQvF2= MXXTRW5IWkWU
NOS-1 NFvLe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTNwOES3OVQh|ryP NFnKTnhUSU6JUlXS
ES1 NHnBZWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTNwOUKyPVMh|ryP MlLHV2FPT1KHUh?=
NCI-H2171 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjKT|hyUUN3ME2zMlkzPDJ|IN88US=> M{\V[HNCVkeURWK=
NCI-H747 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTNwOUSyNlEh|ryP NVTmN3lVW0GQR2LFVi=>
MHH-NB-11 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPJUIpKSzVyPUOuPVU{OTJizszN MULTRW5IWkWU
MZ1-PC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXRTWM2OD1|Lkm5NlQh|ryP MlrmV2FPT1KHUh?=
MMAC-SF MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z4fWlEPTB;ND6wNlQ3PyEQvF2= NEXXOmFUSU6JUlXS
NMC-G1 NGDJcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O0XGlEPTB;ND6yNlczOyEQvF2= M375fnNCVkeURWK=
SW872 NYfOdnRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfmdpRKSzVyPUSuN|Q{PCEQvF2= M{nRcnNCVkeURWK=
TE-12 NFPae4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CyfWlEPTB;ND61OlM6PCEQvF2= NVnzd5d1W0GQR2LFVi=>
LU-139 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTRwNkG4N|Uh|ryP M3\VU3NCVkeURWK=
HC-1 M13LPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLZTWM2OD12Lk[5OFk1KM7:TR?= M4e2dHNCVkeURWK=
COR-L279 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f3PGlEPTB;ND63OVg6OSEQvF2= NFi2VGZUSU6JUlXS
SF268 NIWyRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;zTWM2OD12Lke5PVE3KM7:TR?= M3e1cnNCVkeURWK=
MC-CAR MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fmfWlEPTB;NT6wOlc2PyEQvF2= NICzOlJUSU6JUlXS
TK10 MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\FenpGUUN3ME21MlM2PDZ7IN88US=> M4THVnNCVkeURWK=
TE-1 NXTidG1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfOPJh6UUN3ME21MlQ6ODB2IN88US=> MWDTRW5IWkWU
NCI-H2126 NELEOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYezZVRGUUN3ME21MlY1PTd2IN88US=> MVLTRW5IWkWU
Daudi MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TnUmlEPTB;NT62PVEzKM7:TR?= NILmOZlUSU6JUlXS
NCI-H1648 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[3NmlEPTB;NT64NVQ2PCEQvF2= NXH3WYNIW0GQR2LFVi=>
OS-RC-2 NI\scIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:zZZBKSzVyPUWuPVg2QTdizszN MVrTRW5IWkWU
DJM-1 NF\nU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTZwM{S2OlYh|ryP NIjXNWxUSU6JUlXS
LS-1034 NVfYN3dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTZwN{W2OkDPxE1? MkTkV2FPT1KHUh?=
NCI-H1581 NFfHTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Xz[2lEPTB;Nj63PFQxPSEQvF2= MoH6V2FPT1KHUh?=
UACC-257 NWraeXhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\FT2lEPTB;Nz6wOFUyOiEQvF2= NHLCOYtUSU6JUlXS
KM-H2 NIXtU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe5[oFKSzVyPUeuNVg1PTdizszN MnLNV2FPT1KHUh?=
NCI-H1436 NE\sPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;HUZd2UUN3ME23MlY6QTN{IN88US=> NFL6epZUSU6JUlXS
IA-LM MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfLTWM2OD15Lki1PUDPxE1? MlrEV2FPT1KHUh?=
NCI-H526 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnSzTWM2OD16LkK1OlM4KM7:TR?= MVzTRW5IWkWU
GCIY NGn3NHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rHOGlEPTB;OD6zOlk3PSEQvF2= NHjzbppUSU6JUlXS
CP67-MEL M4jRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu5SYUzUUN3ME24MlU{OjZizszN NGT3eHVUSU6JUlXS
KALS-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W0W2lEPTB;OD64N|g2OSEQvF2= M3jqdHNCVkeURWK=
NCI-H1770 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\kRmlEPTB;OD65NFI3PSEQvF2= NHvtenJUSU6JUlXS
8-MG-BA Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LIZ2lEPTB;OT6zNlg1PCEQvF2= Mo\LV2FPT1KHUh?=
KY821 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTlwN{e0PFQh|ryP MUXTRW5IWkWU
SNB75 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PSSGlEPTB;MUCuNFc3KM7:TR?= M{\5XHNCVkeURWK=
NCCIT MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfzTWM2OD1zMT6wOVgzKM7:TR?= MlvMV2FPT1KHUh?=
SJSA-1 M3jBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPOTGhKSzVyPUGxMlI5QTFizszN MW\TRW5IWkWU
LB373-MEL-D M17UdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTFzLkO4Nlch|ryP Mnm2V2FPT1KHUh?=
TALL-1 NIL6TlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLPV5prUUN3ME2xNU41ODV6IN88US=> NYWzW5czW0GQR2LFVi=>
NB69 NFjWfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfWd4RRUUN3ME2xNU44PzB3IN88US=> MYTTRW5IWkWU
NCI-H1355 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFzLkm0NlYh|ryP MYfTRW5IWkWU
DMS-153 NXzhO4d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTZ[WpzUUN3ME2xNk4xPDJ4IN88US=> Mnz3V2FPT1KHUh?=
OPM-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTF{LkG1PVYh|ryP NELUfYpUSU6JUlXS
NB1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrPTGNuUUN3ME2xNk4zQSEQvF2= MlexV2FPT1KHUh?=
A3-KAW NVfGcI1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF{LkOyN|Yh|ryP Mn32V2FPT1KHUh?=
NCI-H1882 NHznfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom3TWM2OD1zMj60NFY3KM7:TR?= M1jUdHNCVkeURWK=
KG-1 M1fh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPrfmpKSzVyPUGyMlY2PDVizszN MoLCV2FPT1KHUh?=
LC4-1 NGDSPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkThTWM2OD1zMj63O|A3KM7:TR?= NYfnXoNzW0GQR2LFVi=>
HCE-T MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3FbndrUUN3ME2xN{4xODR7IN88US=> MV;TRW5IWkWU
NEC8 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrobG1KSzVyPUGzMlExOzhizszN NFftVWtUSU6JUlXS
IST-MEL1 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLsTWM2OD1zMz61O|g5KM7:TR?= NF71dI9USU6JUlXS
EW-3 NV2xSW5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn5XpNKSzVyPUGzMlc1ODJizszN M2fB[3NCVkeURWK=
CTB-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli3TWM2OD1zND6wN|I6KM7:TR?= NFnPXppUSU6JUlXS
LS-123 NXHhfpdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W2SGlEPTB;MUSuNVU5QCEQvF2= M1jLdHNCVkeURWK=
NCI-H1417 M4TBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF2LkOwOVIh|ryP NHq0VY5USU6JUlXS
MZ7-mel M4XSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fCUmlEPTB;MUSuOFQ{OyEQvF2= MkjIV2FPT1KHUh?=
JiyoyeP-2003 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrVTWM2OD1zNT62N|I3KM7:TR?= M2XQU3NCVkeURWK=
ES6 NIGxSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfMTWM2OD1zNj6yN|YyKM7:TR?= MX7TRW5IWkWU
HH NH;OelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLOTWM2OD1zNz6xPVY{KM7:TR?= NUTKblFpW0GQR2LFVi=>
SF539 MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7TSGFKSzVyPUG3Mlk6OjJizszN MWjTRW5IWkWU
Calu-6 NXn4c3pJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[5eXpNUUN3ME2xPU4zOzlizszN NXrXc2hwW0GQR2LFVi=>
SK-MM-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljTTWM2OD1zOT61OVUh|ryP M2[wcnNCVkeURWK=
IST-MES1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vNcmlEPTB;MUmuOlY3OyEQvF2= NFzBS2dUSU6JUlXS
GI-ME-N MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTF7LkiyNlch|ryP NUT0R5R7W0GQR2LFVi=>
CAL-148 NX[xeZQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37qOWlEPTB;MkCuPVk{PCEQvF2= MoDLV2FPT1KHUh?=
EVSA-T MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJzLkG0PVkh|ryP Mni1V2FPT1KHUh?=
LP-1 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PHWGlEPTB;MkGuN|Q{OiEQvF2= M{XPeXNCVkeURWK=
BOKU NWDEVWNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LCN2lEPTB;MkGuOFU{OyEQvF2= NHfWN5RUSU6JUlXS
KLE NInxb21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrjTWM2OD1{Mj6xPVA{KM7:TR?= NG\xcIpUSU6JUlXS
LB831-BLC MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJ3LkG1NlYh|ryP MYPTRW5IWkWU
NCI-H889 NGDsfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rvRmlEPTB;MkWuNVk{OSEQvF2= MV;TRW5IWkWU
REH NFvhOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLyNYhKSzVyPUK1MlQ3PzFizszN NXP3cG9uW0GQR2LFVi=>
KP-N-RT-BM-1 NF;PSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXETWM2OD1{NT60O|UzKM7:TR?= NUGwOHFtW0GQR2LFVi=>
MPP-89 MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3CWXhKSzVyPUK1MlU{OTRizszN NGW3cI5USU6JUlXS
no-11 NYjNOnBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jWfWlEPTB;MkWuO|Q4KM7:TR?= MWTTRW5IWkWU
NCI-H748 M4i0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrZW25KSzVyPUK1Mlc3OjdizszN M4fEc3NCVkeURWK=
LB2518-MEL NGGxV|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HYWWlEPTB;MkeuNVc4OyEQvF2= M1\xWHNCVkeURWK=
TGBC1TKB NIjMUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7PUnBKSzVyPUK3MlU2QDVizszN M{PX[3NCVkeURWK=
MHH-PREB-1 M2LKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3jc3V3UUN3ME2yPE4xPzN2IN88US=> Mlv1V2FPT1KHUh?=
MZ2-MEL M4jDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojNTWM2OD1{OD62NVQ{KM7:TR?= MonDV2FPT1KHUh?=
U-266 NFvNO|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLiTJNKSzVyPUK4MlY{PjZizszN MVzTRW5IWkWU
SNU-C1 MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fZe2lEPTB;MkiuPVQ{KM7:TR?= MYLTRW5IWkWU
SW962 NFP6U|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz5N5dKSzVyPUOwMlI4PDdizszN NF\Ne|FUSU6JUlXS
Raji NFmxcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNyLkW1PVIh|ryP M3z4OnNCVkeURWK=
KNS-42 NH;2VFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rtOWlEPTB;M{CuPFk2PiEQvF2= NFfONGxUSU6JUlXS
LB996-RCC NX31fGl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHjRYdKSzVyPUOxMlE4ODJizszN NXW4flR[W0GQR2LFVi=>
CHP-126 MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[5epJoUUN3ME2zNU4yQTh2IN88US=> MlHPV2FPT1KHUh?=
RXF393 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnFV4sxUUN3ME2zNk41QTdizszN MY\TRW5IWkWU
COLO-684 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTN{Lk[0N|gh|ryP M13LTHNCVkeURWK=
A704 NIHVfoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX36S3h6UUN3ME2zN{42PTN6IN88US=> MmDiV2FPT1KHUh?=
A253 M{PqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLIWZFKSzVyPUOzMlU5PTJizszN MnvRV2FPT1KHUh?=
KNS-81-FD NHzYfItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDDdVNKSzVyPUO0MlU1PTZizszN Mm\wV2FPT1KHUh?=
TE-441-T Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj3c2xKSzVyPUO0MlY{PzFizszN MXTTRW5IWkWU
HCC2157 M2rOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTN3LkS2NVkh|ryP NFHlbnZUSU6JUlXS
ES3 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\VeGlEPTB;M{[uOlc2KM7:TR?= NFexNGVUSU6JUlXS
NCI-H1155 NEPFU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\xVGlEPTB;M{euPFE2KM7:TR?= MWDTRW5IWkWU
SNU-C2B NYTmWXpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33QSmlEPTB;M{iuNVY2PCEQvF2= M4rTR3NCVkeURWK=
JAR M3O0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn23TWM2OD1|OD6yOFQ6KM7:TR?= MXrTRW5IWkWU
GDM-1 M4\0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Hqb2lEPTB;M{iuPVEyPiEQvF2= M4\1PHNCVkeURWK=
KU812 M1\Fe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HHfGlEPTB;NEGuOVA4KM7:TR?= MoTXV2FPT1KHUh?=
BC-1 NFXZWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTR{Lk[3N|Eh|ryP M{LubnNCVkeURWK=
GI-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTR{LkmxPVIh|ryP NW\t[VVoW0GQR2LFVi=>
NCI-H1694 NEm3[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTwOIVKSzVyPUS0Mlk1PzJizszN NG\lNIdUSU6JUlXS
DG-75 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPON3pGUUN3ME20OU4yPTd5IN88US=> NIHa[FFUSU6JUlXS
COR-L88 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vHTGlEPTB;NEWuNlc4QCEQvF2= MljDV2FPT1KHUh?=
LS-513 NWT1dG9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTR3LkmxOVYh|ryP NFX4UlFUSU6JUlXS
HD-MY-Z NUnLTVl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;WTWM2OD12Nj60OlEzKM7:TR?= MVjTRW5IWkWU
L-363 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\BTWM2OD12Nj64PFEh|ryP MkPuV2FPT1KHUh?=
TE-6 NEnncY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHDTWM2OD12OD60OFYh|ryP MUfTRW5IWkWU
NCI-H345 NVniWWFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn6yTWM2OD12OD60Olgh|ryP M1uwO3NCVkeURWK=
TE-5 M162Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzwXlBIUUN3ME20PU44OTF6IN88US=> NXKxNJV7W0GQR2LFVi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DLK / p-MKK7 / MKK7 / p-JNK / JNK ; 

PubMed: 23431148     


Western blot of the DLK pathway members in RGCs (retinal ganglion cells) 4 h after immunopanning in the presence of 0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, or 2 μM tozasertib. 

p-AURKA / AURKA / Survivin ; 

PubMed: 28218735     


BGC823 cells were incubated with indicated doses of VX-680 for 24 h before subjected to western blotting with the indicated antibodies. Densitometry was used to quantify the Survivin and GAPDH levels. The relative expression shown (right panel) are means±s.e.m. of the ratios of Survivin to GAPDH. 

YAP; 

PubMed: 31160567     


Western blot analysis of YAP protein level in A549 cells treated with indicated doses of VX-680 for 24 h. 

p-AKT / p-GSK3β / Cleaved caspase-3 / Cleaved PARP ; 

PubMed: 21600017     


NB4-R2 cells were collected, lysed and subjected to Western blot analysis with cleaved caspase-3, cleaved-PARP, pAkt-1 (Ser473), pGSK-3β (Ser9) specific antibodies. GAPDH was used as a loading control. Data shown is a representative of three independent experiments.

23431148 28218735 31160567 21600017
Immunofluorescence
α-tubulin / Aurora-A ; 

PubMed: 21600017     


The morphology of mitotic spindle was shown by immunofluorescence staining with anti-α-tubulin antibody and anti-Aur-A antibodies. Microtubules were stained as green, Aur-A protein as red, and nucleus as blue.

21600017
Growth inhibition assay
Cell viability; 

PubMed: 21600017     


VX-680 significantly suppresses the proliferation in a number of leukemic cell types. OCI-AML3, NB4, HL-60 and ML-1 cells were incubated with increasing doses of VX-680 (1, 2, 5 and 10 nM) for 24 hr. Cell viability was measured by MTT assay. Data summarized three independent experiments, *p < 0.05, **p < 0.01, compared to control.

21600017
In vivo VX-680 gives rise to a marked decrease in tumor size in a human AML (HL-60) xenograft model. In mude mice treateed with VX-680 at 75 mg/kg, twice a day intraperitoneally (b.i.d. i.p.) for 13 days, mean tumor volumes are reduced by 98%. Tumor growth decrease is dose dependent and significant at a dose of 12.5 mg/kg b.i.d. VX-680 is well tolerated, with a small decrease in body weight observed only at the highest dose. VX-680 also triggers tumor regresson in pancreatic and colon xenograft models. VX-680 also displays potent antitumor activity when infused i.v. in mude rats bearing established HCT116 tumors. A higher dose of VX-680 (2 mg/kg/h) improves efficacy with a 56% decrease in mean tumor volume. [1]

Protocol

Kinase Assay:

[3]

- Collapse

Kinase inhibition assays:

The consumption of ATP is coupled via the pyruvate kinase/lactic dehydrogenase enzyme pair to the oxidation of NADH, which can be monitored through the decrease in absorption at 340 nm. Reactions contains 100 mM Tris (pH 8), 10 mM MgCl2, 2.2 mM ATP, 1 mM phosphoenolpyruvate, 0.6 mg/mL NADH, 75 units/mL pyruvate kinase, 105 units/mL lactate dehydrogenase, and 0.5 mM substrate peptide (sequence: EAIYAAPFAKKK). Reactions (75 μL) are started by adding sufficient kinase to bring the reactions to 30 nM kinase concentration and the decrease in absorbance is monitored over 30 minutes at 30°C in a microtiter plate spectrophotometer. Inhibitory constants are obtained through addition of 3.75 μL VX-680 in 100% DMSO or DMSO alone. Ki values are calculated as follows, K i = IC50 / (1 + [S]/Kd), where [S] = [ATP] = 2.2 mM, and Kd (of ATP to Abl) = 70 μM. These values are calculated assuming a Kd (ATP) of 70 μM for wild type and H396P Abl kinase domain.
Cell Research:

[2]

- Collapse
  • Cell lines: CAL-62 cells
  • Concentrations: 5-500 nM
  • Incubation Time: 4 days
  • Method:

    The CAL-62 cells are cultured in the absence (dimethyl sulfoxide, DMSO) or the presence of 500  nM VX-680 for different periods of time (1-5 days). The dose-dependent effects of VX-680 on cell proliferation are evaluated by treating the different ATC cells for 4 days with different concentrations of the Aurora inhibitor (5–500  nM). The cells are pulse labeled with 30  mM BrdU for 2  hours before the end of the incubation time. The BrdU incorporation is analyzed by means of a colorimetric immunoassay using the cell proliferation ELISA kit. The results from VX-680-treated cells are compared with those observed in control cells and expressed as a fold of variation versus control.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Female athymic NCr-nu mice bearing HL-60 leukemia cells
  • Formulation: 50% PEG300 in 50 mM phosphate buffer
  • Dosages: 50 mg/kg, 75 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (200.17 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.59
Formula

C23H28N8OS

CAS No. 639089-54-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457) supplier | purchase Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457) cost | Tozasertib (VX-680, MK-0457) manufacturer | order Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID